Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Shares Issued (2017 - 2025)

Intellia Therapeutics (NTLA) has disclosed Shares Issued for 10 consecutive years, with $625000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued fell 99.64% to $625000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $722000.0, a 99.59% decrease, with the full-year FY2025 number at $722000.0, down 99.59% from a year prior.
  • Shares Issued was $625000.0 for Q4 2025 at Intellia Therapeutics, up from -$1.1 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $400.0 million in Q1 2022 to a low of -$386.7 million in Q2 2022.
  • A 5-year average of $41.1 million and a median of $762000.0 in 2021 define the central range for Shares Issued.
  • Biggest YoY gain for Shares Issued was 13368.75% in 2021; the steepest drop was 13007.45% in 2021.
  • Intellia Therapeutics' Shares Issued stood at $762000.0 in 2021, then soared by 52253.28% to $398.9 million in 2022, then tumbled by 70.49% to $117.7 million in 2023, then soared by 48.82% to $175.2 million in 2024, then crashed by 99.64% to $625000.0 in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Shares Issued are $625000.0 (Q4 2025), -$1.1 million (Q3 2025), and $1.2 million (Q2 2025).